EZH2 and neoplasm: Because tumor progression in these models involves a shift from AR-positive CRPC to AR-negative NEPC, we propose that EZH2 and PI3K/mTOR inhibitor co-treatment is particularly effective in castrate conditions due to EZH2 inhibition restoring AR expression and function.